Orthotopic and metastasis models for preclinical efficacy testing of novel cancer drugs

Introduction

This Pharmatest White Paper addresses the lack of efficacy that is a major cause of attrition in clinical development of new oncology compounds by showing how selecting the correct and the most predictive animal models for research is critical before entering clinical efficacy studies.

It discusses the key factors in model selection including assessing the tumor microenvironment, testing immunomodulatory drugs in intact immune systems, testing compounds in metastasized disease and evaluating potential adverse effects in treatment-induced bone loss.

It also presents an array of cancer and skeletal disease models that take into account these crucial elements in developing novel antitumor therapies, allowing efficacy testing of compounds in broad experimental settings with improved clinical predictivity.

Supplier Information
Supplier: Pharmatest Services Ltd
Address: Itäinen Pitkäkatu 4 C, 5th floor, 20520 Turku, Finland
Tel: +358 2 278 4700
Fax: +358 2 278 4710
Website: www.pharmatest.com